| Autor: |
Ibáñez Gaspar V; School of Biomolecular and Biomedical Sciences, Conway Institute, University College Dublin, Dublin, Ireland., McCaul J; School of Biomolecular and Biomedical Sciences, Conway Institute, University College Dublin, Dublin, Ireland., Cassidy H; School of Biomolecular and Biomedical Sciences, Conway Institute, University College Dublin, Dublin, Ireland.; Systems Biology Ireland, School of Medicine, University College Dublin, Belfield, Dublin, Ireland., Slattery C; School of Biomolecular and Biomedical Sciences, Conway Institute, University College Dublin, Dublin, Ireland., McMorrow T; School of Biomolecular and Biomedical Sciences, Conway Institute, University College Dublin, Dublin, Ireland. |
| Abstrakt: |
The natural compound curcumin has been shown to have therapeutic potential against a wide range of diseases such as cancer. Curcumin reduces cell viability of renal cell carcinoma (RCC) cells when combined with TNF-related apoptosis-inducing ligand (TRAIL), a cytokine that specifically targets cancer cells, by helping overcome TRAIL resistance. However, the therapeutic effects of curcumin are limited by its low bioavailability. Similar compounds to curcumin with higher bioavailability, such as demethoxycurcumin (DMC) and 3,5-bis(2-fluorobenzylidene)-4-piperidone (EF24), can potentially have similar anticancer effects and show a similar synergy with TRAIL, thus reducing RCC viability. This study aims to show the effects of DMC and EF24 in combination with TRAIL at reducing ACHN cell viability and ACHN cell migration. It also shows the changes in death receptor 4 (DR4) expression after treatment with these compounds individually and in combination with TRAIL, which can play a role in their mechanism of action. |
